TET2 and non-small cell lung carcinoma: [124] report conflicting data in their NSCLC patient cohort (n = 108), where patients with a TET2 mutation (n = 12) had a significantly longer OS compared to patients without TET2 mutation (n = 96) (HR [95% CI] = 0.15 [0.03–0.9]) (Table 3).